[1] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版). 中华肝脏病杂志. 2020,28(2):112-113.
[2] Bray F, Ferlayme J, Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2018,68(6),394-424.
[3] Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J,1992,11(11),3887-3896.
[4] Ahmadzadeh M, Johnson L, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. BLOOD,2009,114(8),1537-1544.
[5] Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer: Molecular mechanisms and polymorphisms. Immunogenetics,2018,70(2).
[6] Ohaegbulam K, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med,015,21(1),24-33.
[7] GonzalezCao M, Morán T, Dalmau J,et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: The phase 2 DURVAST study. JAMA Oncol,2020,6(7):1063-1067.?
[8] MLdrick Ts, Goncalves Ph, Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced Cancer-A phase 1 study. JAMA Oncol,2019,5(9):1332-1339.
[9] Omid H, Caroline R, Adil D, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. New Engl J Med,2013,369(2),134-144.
[10] Tumeh P, Harview C, Yearley J, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature,2014,515(7528),568-571.
[11] Zhang X, Zhou YX, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer,2019,7(1):322.
[12] Lee PC, Chao Y, Chen MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer,2020,8(2) :e001072.
[13] 李鹏尉, 沈宇清. 免疫检查点分子在慢性HBV感染中对t细胞功能影响的研究进展. 病毒学报, 2021,37(2):465-470.
[14] Ferrari C. HBV and the immune response. Liver Int,2015,35 Suppl 1:121-128. |
